Market Intelligence
The ProGen Radar
Fortnightly market intelligence on radiopharma, CDMO, ADC, and cell and gene therapy. Built from live executive search mandates and operator conversations.
The Newsletter
Read it free on LinkedIn or by email
The Radar is a fortnightly briefing on what is actually moving across radiopharma, CDMO, ADC, and cell and gene therapy. Sector pulse, deal flow, talent shifts, and the operator-level signal behind the headlines.
Written by Byron Fitzgerald from live executive search mandates. No filler, no recycled press releases. Read by VPs and C-suite at biotechs, CDMOs, and investors across life sciences.
4,000+
Email subscribers across life sciences
33,000+
LinkedIn followers reading each issue
Newsletter
Get the ProGen Radar
Free, fortnightly, by email. Same signal that runs on LinkedIn.
No spam. Unsubscribe anytime.
What is inside each issue
A tight fortnightly read on the modalities that matter, drawn from live mandates and operator conversations.
The Setup - what shifted this fortnight, and why it matters
Sector Pulse: Radiopharma - what is moving in the sector
Sector Pulse: CGT - cell and gene therapy signal
Sector Pulse: ADC - antibody-drug conjugates
Deal Flow Watch - capital movements, M&A signal, partnership economics
People Moves - senior hires and exits worth knowing about
Why I write this
I run retained executive search at VP to C-suite level across radiopharma, CDMO, ADC, and cell and gene therapy. That means I see the operator-level signal before it shows up in press releases. The hires that telegraph commercial strategy. The deal-flow patterns that precede consolidation. The capacity moves that change competitive dynamics.
The Radar is where I write that down. Not desk research. Not sector commentary. Actual signal from inside live mandates and operator rooms.
Byron Fitzgerald, Founder, ProGen Search
What to Expect
Questions, answered
What does the Radar cover?
Radiopharma, CGT, and ADCs, with CDMO and supply-chain signal throughout. Heaviest on radiopharma, given current market activity.
How often is it sent?
Fortnightly, by email, with the same signal running on LinkedIn.
What does it cost?
Nothing. The Radar is free. Unsubscribe anytime from the link in any issue.
Who reads it?
VPs and C-suite at biotechs, CDMOs, and investors across life sciences.